deamidation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
== Extraction == After finishing the digestion the peptides generated in this process have to be extracted from the gel matrix. This is accomplished by one or several extraction steps. The gel particles are incubated with an extraction solution and the supernatant is collected. In the first extraction, almost all of the peptide is recovered, the repetition of the extraction step can increase the yield of the whole process by only 5-10%. To meet the requirements of peptides with different physical and chemical properties an iterative extraction with basic or acidic solutions is performed. For the extraction of acidic peptides a solution similar to the concentration and composition of the digestion buffer is used; basic peptides are extracted in dependence to the intended mass spectrometric method with a low concentrated acidic solution of formic acid for ESI and trifluoroacetic acid for MALDI respectively. Studies on model proteins showed a recovery of approximately 70–80% of the expected peptide yield by extraction from the gel. Many protocols contain an additional fraction of acetonitrile to the extraction solution which, in concentrations above 30% (v/v), is effective in reducing the adsorption of peptides to the surface of reaction tubes and pipette tips. The liquid of the pooled extracts is evaporated in a centrifugal evaporator. If the volatile salt ammonium bicarbonate was used for the basic extraction, it is partially removed in the drying process. The dried peptides can be stored at -20 °C for at least six months.
The direct cost of border control is hundreds of billions to the United States government alone. Although the indirect economic costs of migration restrictions are much less well studied than those of trade barriers, some economists estimate that the indirect economic cost of border controls cost many trillions of dollars and the size of the global economy could double if migration restrictions were lifted. Immigration can in some cases reduce wages or worsen economic life-cycle assessments. Global border controls have been associated with more than 63,000 border deaths since 2000, although scholars estimate that border deaths are significantly underestimated. Governments often blame unauthorized border crossers for taking excessive risks. Some unauthorized border crossers describe they choose dangerous methods of border crossing when safe and legal avenues are closed. In some cases, enforcement tactics have rerouted migrants to more dangerous routes with the stated goal to deter border crossers with the increased danger. Efforts to make unauthorized immigration more difficult may promote permanent settlement in place of earlier patterns of temporary migration.
== Relation to humans == Arapaima is exploited in many ways by local human populations. Its tongue is thought to have medicinal qualities in South America. It is dried and combined with guarana bark, which is grated and mixed into water. Doses are given to kill intestinal worms. The bony tongue is used to scrape cylinders of dried guarana, an ingredient in some beverages, and the bony scales are used as nail files. Arapaima produce boneless steaks and are considered a delicacy. In the Amazon region, locals often salt and dry the meat, rolling it into a cigar-style package that is then tied and can be stored without rotting, which is important in a region with little refrigeration. Arapaima are referred to as the "cod of the Amazon", and can be prepared in the same way as traditional salted cod. Designers have begun using the skin of the arapaima as leather to make jackets, shoes, and handbags, and to cover furniture. In July 2009, villagers around Kenyir Lake in Terengganu, Malaysia, reported sighting A. gigas. The "Kenyir monster", or "dragon fish" as the locals call it, was claimed to be responsible for the mysterious drowning of two men on 17 June. In August 2018, India Times reported that arapaima has been spotted in the Chalakudy River, following floods in Kerala; their presence in India is attributed to illegal importation for fish farming. The arapaima is depicted on both the flag and the seal of the Department of Ucayali, Peru.
== Clinical trials == Sulanemadlin is notable as the first stapled peptide, a novel pharmaceutical strategy, to enter clinical trials. Despite its preclinical promise, concerns about side effects, including severe neutropenia, have terminated Phase 1B clinical trials early in at least one trial.
Sources: en.wikipedia.org
== Biomedical applications == The oldest application is also the simplest: the surgical suture. Braided silk is easy to handle and holds a knot securely, and it remains in clinical use, although it can provoke a tissue reaction and lose strength over time, and synthetic threads have replaced it in some procedures. Porous silk scaffolds serve as temporary frameworks for regrowing tissue. Because their strength can be set and their degradation slowed, they suit tissues that either bear load or heal slowly—bone, cartilage, skin, and connective tissues such as ligament and tendon, where the toughness of silk is an advantage. Cells are seeded onto the scaffold, which provides mechanical support while they become established and is gradually replaced by the body's own tissue. Silk films, gels and particles can hold a drug and release it slowly. The mild, water-based processing is the principal advantage: sensitive drugs and proteins survive incorporation, and release can be slowed by increasing the beta-sheet content of the surrounding silk. Silk coatings have also been used to stabilise vaccines and other biologics against heat. Thin silk films are transparent, can be moulded with fine surface patterns and dissolve in the body, a combination well suited to biodegradable electronics and optics. Silicon components have been fabricated on silk films designed to conform to tissue and then dissolve once their function is complete, an approach known as transient or bioresorbable electronics. Silk has also been formed into lenses, diffraction gratings and sensors.
At higher temperatures, the fluid starts to behave more like an ideal gas, with a more linear density/pressure relationship, as can be seen in Figure 2. For carbon dioxide at 400 K, the density increases almost linearly with pressure. Many pressurized gases are actually supercritical fluids. For example, nitrogen has a critical point of 126.2 K (−147.0 °C; −232.5 °F) and 3.4 MPa (34 bar). Therefore, nitrogen (or compressed air) in a gas cylinder above this pressure is actually a supercritical fluid. These are more often known as permanent gases. At room temperature, they are well above their critical temperature, and therefore behave as a nearly ideal gas, similar to CO2 at 400 K above. However, they cannot be liquified by mechanical pressure unless cooled below their critical temperature, requiring gravitational pressure such as within gas giants to produce a liquid or solid at high temperatures. Above the critical temperature, elevated pressures can increase the density enough that the SCF exhibits liquid-like density and behaviour. At very high pressures, an SCF can be compressed into a solid because the melting curve extends to the right of the critical point in the P/T phase diagram. While the pressure required to compress supercritical CO2 into a solid can be, depending on the temperature, as low as 570 MPa, that required to solidify supercritical water is 14,000 MPa. The Fisher–Widom line, the Widom line, or the Frenkel line are thermodynamic concepts that allow to distinguish liquid-like and gas-like states within the supercritical fluid.
=== Reducing filament evaporation === During ordinary operation, the tungsten of the filament evaporates; hotter, more-efficient filaments evaporate faster. Because of this, the lifetime of a filament lamp is a trade-off between efficiency and longevity. The trade-off is typically set to provide a lifetime of 1,000 to 2,000 hours for lamps used for general illumination. Theatrical, photographic, and projection lamps may have a useful life of only a few hours, trading life expectancy for high output in a compact form. Long-life general service lamps have lower efficiency, but prior to the development of compact fluorescent and LED lamps they were useful in applications where the bulb was difficult to change. Irving Langmuir found that an inert gas, instead of vacuum, would retard evaporation. General service incandescent light bulbs over about 25 watts in rating are now filled with a mixture of mostly argon and some nitrogen, or sometimes krypton. While inert gas reduces filament evaporation, it also conducts heat from the filament, thereby cooling the filament and reducing efficiency. At constant pressure and temperature, the thermal conductivity of a gas depends upon the molecular weight of the gas and the cross sectional area of the gas molecules. Higher molecular weight gases have lower thermal conductivity, because both the molecular weight and cross sectional area are higher. Xenon gas improves efficiency because of its high molecular weight, but is also more expensive, so its use is limited to smaller lamps.
Crystallography is the science that examines the arrangement of atoms in crystalline solids. Crystallography is a useful tool for materials scientists. One of the fundamental concepts regarding the crystal structure of a material includes the unit cell, which is the smallest unit of a crystal lattice (space lattice) that repeats to make up the macroscopic crystal structure. Most common structural materials include parallelepiped and hexagonal lattice types. In single crystals, the effects of the crystalline arrangement of atoms is often easy to see macroscopically, because the natural shapes of crystals reflect the atomic structure. Further, physical properties are often controlled by crystalline defects. The understanding of crystal structures is an important prerequisite for understanding crystallographic defects. Examples of crystal defects consist of dislocations including edges, screws, vacancies, self inter-stitials, and more that are linear, planar, and three dimensional types of defects. New and advanced materials that are being developed include nanomaterials, biomaterials. Mostly, materials do not occur as a single crystal, but in polycrystalline form, as an aggregate of small crystals or grains with different orientations. Because of this, the powder diffraction method, which uses diffraction patterns of polycrystalline samples with a large number of crystals, plays an important role in structural determination. Most materials have a crystalline structure, but some important materials do not exhibit regular crystal structure.
=== Biological properties === Chitosan is biodegradable and biocompatible. Chitosan enhances the transport of polar drugs across epithelial surfaces. The enhanced chitosan uptake is mainly due to the interaction of positively charged chitosan with cell membranes, activation of chlorine–bicarbonate exchange channels, and reorganization of proteins associated with epithelial tight junctions, thus opening epithelial tight junctions. However, it is not approved by the FDA for drug delivery. Purified quantities of chitosan are available for biomedical applications. Chitosan inhibits the growth of different bacteria and fungi by mechanisms involving several factors, including the degree of deacetylation, pH, divalent cations, and solvent type.
Sources: en.wikipedia.org
The 2024 edition of the FAO report The State of Food and Agriculture 2024 adopts an agrifood systems typology with six categories – protracted crisis, traditional, expanding, diversifying, formalizing and industrial – to reveal that different systems face unique challenges and require targeted interventions. The typology uses a set of four variables, comprising agricultural value added per worker, number of supermarkets per capita, diet diversity, and urbanization. It is based on the food systems typology developed by Marshall et al. (2021) with the aim to offer a distinct classification of countries based on various aspects of their national agrifood systems, serving as a valuable addition to context-specific studies. The FAO typology adds the category for protracted crises to address the major disruptions caused by prolonged conflicts and vulnerabilities in agrifood systems, following the designation made in the "Global Report on Food Crises."
South African officials stated that the country had initially expected to attend the summit, while the French government denied having yielded to foreign pressure over the invitation list. Kenya was invited as one of the African partner countries. In late 2025, Macron reportedly considered inviting Chinese leader Xi Jinping to the Évian summit. Japan expressed concern to France that a Chinese invitation could affect G7 unity, amid heightened China–Japan diplomatic tensions.
== Apolipoprotein H involvement == β2-glycoprotein I has been identified as apolipoprotein H and is required for the recognition of ACA in autoimmune disease. Only a subset of autoimmune anti-cardiolipin antibodies bind Apo-H, these anti-apolipoprotein antibodies are associated with increased thrombosis.
== Function (translocation) == Signal peptides function to prompt a cell to translocate the protein, usually to the cellular membrane. In prokaryotes, signal peptides direct the newly synthesized protein to the SecYEG protein-conducting channel, which is present in the plasma membrane. A homologous system exists in eukaryotes, where the signal peptide directs the newly synthesized protein to the Sec61 channel, which shares structural and sequence homology with SecYEG, but is present in the endoplasmic reticulum. Both the SecYEG and Sec61 channels are commonly referred to as the translocon, and transit through this channel is known as translocation. While secreted proteins are threaded through the channel, transmembrane domains may diffuse across a lateral gate in the translocon to partition into the surrounding membrane.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.